BIOTECanada Responds to CDA-AMC Guidance for Incorporating Impacts on Informal Caregivers and Productivity Outcomes in Economic Evaluations.

Why It Matters

Integrating caregiver and productivity metrics broadens the value framework for new therapies, potentially reshaping reimbursement criteria across Canada’s health system.

Key Takeaways

• BIOTECanada urges societal perspective for every HTA submission
• Guidance currently limits caregiver data to select product categories
• Flexibility in data sources could reduce sponsor burden
• Clear linkage of data to reimbursement decisions needed
• Methodological appendix offers practical tools for evaluating caregiver impact

Pulse Analysis

Health technology assessment (HTA) in Canada is at a crossroads as the Canadian Drug Agency (CDA‑AMC) drafts guidance to embed informal caregiver quality‑of‑life and productivity effects into economic models. Traditionally, HTA has focused on direct medical costs and patient outcomes, but mounting evidence shows that caregivers bear substantial health and economic burdens. By acknowledging these indirect costs, policymakers aim to capture the full societal value of innovative therapies, aligning reimbursement decisions with real‑world impact.

BIOTECanada’s response, co‑authored with Innovative Medicines Canada, pushes the draft further by urging a universal societal perspective for all submission types. The group argues that limiting caregiver data to specific product categories creates inconsistency and may undervalue treatments that alleviate caregiver strain. Their recommendations include clearer guidance on how collected data will be weighted in funding decisions and a call for flexibility in data sources, reducing the administrative load on sponsors while maintaining methodological rigor. The accompanying appendix outlines practical steps for measuring caregiver health‑related quality of life and productivity losses.

If adopted, these recommendations could reshape the Canadian pharmaceutical landscape. Companies would need to incorporate caregiver metrics early in trial design, potentially influencing development pipelines and pricing strategies. Payers, in turn, would have richer evidence to justify coverage of high‑cost therapies that deliver broader societal benefits. The move mirrors trends in Europe and the United States, where HTA bodies increasingly recognize indirect costs, signaling a more holistic approach to valuing health innovations.